Earnings analysis · 10-Q
LTGO earnings analysis
Filed September 3, 2026 · Our reading of the company's report
The latest report
Latigo remains a pre-revenue clinical-stage biotechnology company with no gross or operating margin to report. Q2 net loss was broadly stable at $25.797 million, but six-month operating cash burn increased to $48.350…
Read full summary
Latigo remains a pre-revenue clinical-stage biotechnology company with no gross or operating margin to report. Q2 net loss was broadly stable at $25.797 million, but six-month operating cash burn increased to $48.350 million and six-month net loss rose to $48.758 million; higher G&A spending offset lower R&D costs. Positive onzotrigine efficacy data and planned Phase 3 trials are meaningful catalysts, while the August IPO's $363.9 million net proceeds materially improve liquidity and are expected to fund operations into 2029. However, the company remains dependent on clinical execution, additional capital over time, third-party suppliers and CROs, and remediation of a material weakness.
Reported figures
- Earnings per share
- $-27.59
- Segment
- One operating and reportable segment; no product revenue. Research and development expense was $21.226 million in Q2 2026 versus $22.924 million in Q2 2025, and $38.859 million for the six months versus $41.612 million.
- Segment
- Within R&D, Q2 2026 direct onzotrigine program costs were $8.566 million versus $9.936 million, while other clinical and non-clinical program costs were $5.559 million versus $7.628 million.
- Segment
- Six-month R&D included $15.256 million of direct onzotrigine costs, $10.205 million for other clinical and non-clinical programs, $10.488 million of personnel-related costs, and $2.910 million of other R&D costs.
What stood out
-
IPO materially strengthens liquidity
The company completed its August 2026 IPO, issuing 22.080 million shares at $18.00 per share and receiving approximately $363.9 million of net proceeds after approximately $33.6 million of offering costs.
-
Runway extended into 2029
Management estimates that cash plus net IPO proceeds will fund projected operating expenses and capital expenditures into 2029. The June 30, 2026 cash balance was $55.003 million before the IPO.
-
Positive lead-program clinical data
High-dose onzotrigine in a 343-patient abdominoplasty trial improved SPID48 versus placebo by 62.1 points with p<0.001 and exceeded the opioid comparator's SPID48 of 40.9. Median time to a 2-point pain reduction was 52 minutes versus 83 minutes for hydrocodone bitartrate/acetaminophen.
-
Quarterly loss per share improved
Q2 net loss improved modestly to $25.797 million from $25.835 million year over year, while basic and diluted loss per share improved to $27.59 from $36.52 because weighted-average shares used in the calculation increased to 935,025 from 707,465.
-
Phase 3 execution milestones ahead
Management plans to initiate a placebo-controlled Phase 3 bunionectomy trial and an open-label Phase 3 safety trial for onzotrigine in the second half of 2026, with topline results expected in the second half of 2027.
-
LTG-321 advances into Phase 2
LTG-321's Phase 2 osteoarthritis trial is designed to enroll approximately 120 patients, with topline results expected in the second half of 2027. The company reported continued pharmacodynamic activity 24 hours after a single dose in Phase 1 data dated May 15, 2026.
What to watch
-
Persistent losses and future financing need
Six-month net loss increased to $48.758 million from $46.787 million, and operating cash burn rose to $48.350 million from $42.716 million. The company states it will require substantial additional capital to complete development despite projecting runway into 2029.
-
Convertible-note and change-of-control exposure
The company issued $35.0 million of convertible notes due in June 2027; the notes carry 5.0% annual interest and a change-of-control repayment premium equal to 100% of outstanding principal. The related derivative liability was $5.148 million at June 30, 2026.
-
Unremediated material weakness
Management disclosed that its disclosure controls were ineffective as of June 30, 2026 because of a material weakness involving segregation of duties, including the ability to create and post manual journal entries without independent review and to prepare and review account reconciliations.
-
Expanded cybersecurity exposure
The filing newly describes a February 2026 business email compromise involving an employee, although vendors identified no material loss. The company also states that it relies significantly on third parties to identify and remediate security incidents.
-
Foreign supply-chain and trade risk
The company relies on suppliers in India for starting materials and active pharmaceutical ingredients and in China for starting materials. It warns that tariffs, sanctions and the BIOSECURE Act could increase R&D costs, disrupt supply and delay development timelines.
-
Concentrated clinical pipeline risk
The company has two product candidates in clinical development—onzotrigine and LTG-321—and states that the FDA may require additional trials or different endpoints. The onzotrigine IND was previously on clinical hold from May 2024 through November 2024.
Management's outlook
No numeric revenue or EPS guidance was provided. Management estimates that cash and cash equivalents together with net IPO proceeds will fund projected operating expenses and capital expenditure requirements into 2029; the company expects R&D expenses and general and administrative expenses to increase as development activities expand and it operates as a public company.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.